Validity of Clinical Signs and Symptoms in Diagnosis of Ovarian Mass
Validity Of Clinical Signs And Symptoms
DOI:
https://doi.org/10.70284/njirm.v5i4.771Keywords:
Ovarian Tumours, validity of clinical findings in ovarian massAbstract
Objective: The main aim for undertaking this study was to find out what was the appropriateness of clinical diagnosis of benign ovarian tumor and compare the results after Histopathological study. Material And Methods: Retrospective files study of 240 cases was carried out to analyze the clinical signs and symptoms and evaluation done of clinical findings, tumour marker study, ultrasonography, and the plan of treatment. Results: Laparotomy was done in 200 cases, clinically ovarian masses were diagnosed as benign in 75%, by Tumor marker i.e. CA125 in 80%, by sonography in 70% and by histopathology in 83%. The study was statistically analyzed. The values in diagnosis of ovarian mass clinically and comparing with other parameters was significant p value<0.05. Conclusion: Clinical signs and symptoms are still important predictors in reaching the diagnosis of benign Ovarian Mass. [ Saluja J NJIRM 2014; 5(4) :67-71]
References
1. DiSaia JP, Creasman WT : The adnexal mass and ovarian cancer, Clinical Gynecologic Oncology. Fourth esdition, Mosby-Year Book Inc, 295 (1993).
2. Connel GJ, Ryan E, Murphy KJ, Prefontaine M : Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol. 70, 930-s932 (1987)
3. Auersperg N, Ota T, Mitchell GW. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer. 2002;12:691–703. [PubMed]
4. Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol
Endocrinol. 2003;1:68.[PMC free article] [PubMed]
5. Mishell DR Jr Noncontraceptive benefits of oral contraceptive.J Reprod Med 1993:38 (12 Suppl):1021-9
6. Grimes DA Godwin AJ. Rubin A.Smith JA.Lacarra M.Ovulation and follicular development associated with three low dose oral contraceptives a randomized controlled trial.Obstet Gynecol 1994:83:29-34.
7. Egarter C.Putz M. Strohmer H Speiser P Wenzl R.Huber I Ovarian function during low dose oral contraceptive use.Contraception 1995:51(6):329-33
8. Grimes DA, Jones LB, Lopez LM, et al; Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 2011 Sep 7;9:CD006134.
9. Quaye L, Gayther SA, Ramus SJ, Di Cioccio RA, McGuire V, Hogdall E, et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res2008;14:5833-9.
10. Ruofford BD, Jacobs IJ , Menon U. feasibility of screening for ovarian cancer using symptoms as selection criterin. BJOG 2007; 114:59
11. Schutter EM,Kenemans P,Sohn C,Kristen P,Crombach G,westermann R,et al.Diagnostic value of pelvic examination ,ultrasound,and serum CA 125 in postmenopausal women with a pelvic mass.An international multicenter study.Cancer 1994:74: 1398-406.
12. T.A.Panoskaltsis, D.A. Moore,D.A. Haidopoulos, and A.G.McIndoe, “Tuberculous peritonitis : part of the differential diagnosis in ovarian cancer, “American Journal of Obstetrics and Gynecology , vol. 182, no. 3, pp. 740-742, 2000.
13. H. Simsek, M.C.Savas, A.Kadayifci, and G. Tatar, “Elevated serum CA125 concentration in patients with tuberculous peritonitis: a case-control study, “American Journal of Gastroenterology, vol .92, no.7, pp 1174-1176, 1997.
14. V.Thakur, U.Mukherjee, and K.Kumar, “Elevated serum cancer antigen 125 levels in advanced abdominal tuberculosis, “ Medical Oncology, vol. 18, pp 289-291, 2001.
15. Brooks SE.Preoperative evaluation of patients with suspected ovarian cancer.Gynecol Oncol1994:(3P12):S80-90.16. Weissman AM, Barloon TJ. Transvaginal ultronography in non-pregnant and postmenopausal women. Am Fam Physcian 1996;53:2065-72.
17. Management of Suspected Ovarian Masses in Premenopausal Women, Royal College of Obstetricians and Gynaecologists (December 2011).
18. Levine D, Brown DL, Andreotti RF, et al; Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society Radiology. 2010 Sep;256(3):943-5. Epub 2010 May 26.
19. Gottlieb WH,Soriano D, Achrion R et al. CA 125 measurement and ultrasonography in borderline tumours of the ovaey. Am J Obstet Gynecol 2000;183:541-6.
20. Yazbek, J Raju, SK. Ben-Nagi, J et al. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian ca Table 1 Age wise distribution.
21. Goff B, Mandel L, Melancon C, Muntz H. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA2004;291:2705-12
2. Connel GJ, Ryan E, Murphy KJ, Prefontaine M : Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol. 70, 930-s932 (1987)
3. Auersperg N, Ota T, Mitchell GW. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer. 2002;12:691–703. [PubMed]
4. Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol
Endocrinol. 2003;1:68.[PMC free article] [PubMed]
5. Mishell DR Jr Noncontraceptive benefits of oral contraceptive.J Reprod Med 1993:38 (12 Suppl):1021-9
6. Grimes DA Godwin AJ. Rubin A.Smith JA.Lacarra M.Ovulation and follicular development associated with three low dose oral contraceptives a randomized controlled trial.Obstet Gynecol 1994:83:29-34.
7. Egarter C.Putz M. Strohmer H Speiser P Wenzl R.Huber I Ovarian function during low dose oral contraceptive use.Contraception 1995:51(6):329-33
8. Grimes DA, Jones LB, Lopez LM, et al; Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 2011 Sep 7;9:CD006134.
9. Quaye L, Gayther SA, Ramus SJ, Di Cioccio RA, McGuire V, Hogdall E, et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res2008;14:5833-9.
10. Ruofford BD, Jacobs IJ , Menon U. feasibility of screening for ovarian cancer using symptoms as selection criterin. BJOG 2007; 114:59
11. Schutter EM,Kenemans P,Sohn C,Kristen P,Crombach G,westermann R,et al.Diagnostic value of pelvic examination ,ultrasound,and serum CA 125 in postmenopausal women with a pelvic mass.An international multicenter study.Cancer 1994:74: 1398-406.
12. T.A.Panoskaltsis, D.A. Moore,D.A. Haidopoulos, and A.G.McIndoe, “Tuberculous peritonitis : part of the differential diagnosis in ovarian cancer, “American Journal of Obstetrics and Gynecology , vol. 182, no. 3, pp. 740-742, 2000.
13. H. Simsek, M.C.Savas, A.Kadayifci, and G. Tatar, “Elevated serum CA125 concentration in patients with tuberculous peritonitis: a case-control study, “American Journal of Gastroenterology, vol .92, no.7, pp 1174-1176, 1997.
14. V.Thakur, U.Mukherjee, and K.Kumar, “Elevated serum cancer antigen 125 levels in advanced abdominal tuberculosis, “ Medical Oncology, vol. 18, pp 289-291, 2001.
15. Brooks SE.Preoperative evaluation of patients with suspected ovarian cancer.Gynecol Oncol1994:(3P12):S80-90.16. Weissman AM, Barloon TJ. Transvaginal ultronography in non-pregnant and postmenopausal women. Am Fam Physcian 1996;53:2065-72.
17. Management of Suspected Ovarian Masses in Premenopausal Women, Royal College of Obstetricians and Gynaecologists (December 2011).
18. Levine D, Brown DL, Andreotti RF, et al; Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society Radiology. 2010 Sep;256(3):943-5. Epub 2010 May 26.
19. Gottlieb WH,Soriano D, Achrion R et al. CA 125 measurement and ultrasonography in borderline tumours of the ovaey. Am J Obstet Gynecol 2000;183:541-6.
20. Yazbek, J Raju, SK. Ben-Nagi, J et al. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian ca Table 1 Age wise distribution.
21. Goff B, Mandel L, Melancon C, Muntz H. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA2004;291:2705-12
Downloads
Published
2018-01-04
How to Cite
Saluja, D. J. K., Roy, D. P. K., & Mahadik, D. K. (2018). Validity of Clinical Signs and Symptoms in Diagnosis of Ovarian Mass: Validity Of Clinical Signs And Symptoms. National Journal of Integrated Research in Medicine, 5(4), 68–72. https://doi.org/10.70284/njirm.v5i4.771
Issue
Section
Original Articles
